RT Journal Article
SR Electronic
T1 Death profiling of hospitalized patients with COVID-19: Experience from a specialized hospital in Bangladesh
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.04.21259979
DO 10.1101/2021.07.04.21259979
A1 Shahed-Morshed, Md.
A1 Mosabbir, Abdullah Al
A1 Hossain, Mohammad Sorowar
YR 2021
UL http://medrxiv.org/content/early/2021/07/06/2021.07.04.21259979.abstract
AB Background The information on characteristics and causes of mortality in deceased patients with coronavirus disease 2019 (COVID-19) is scarce in the literature. This study aimed to document the clinical profile with causes of death in deceased patients admitted in a COVID-19 dedicated hospital in Dhaka, Bangladesh.Methods This cross-sectional retrospective study included 108 COVID-19 associated deceased patients admitted in Kurmitola general hospital, Dhaka, Bangladesh between 25 March 2020 and 24 June 2020) Data were collected from hospital record. Causes of death were categorized into early and late with cut-off of 48 hours of hospitalization.Results Among 809 hospitalized cases of COVID-19, 108 patient died (13.35%) over three months of study period. The mean age of the deceased patients was 60.22±13.94 years; 86.1% were male. About 85% had at least one comorbidity with diabetes mellitus (65.7%) was the most common one. The most common symptoms were breathlessness (88.0%), fever (65.7%) and cough (43.5%). Nearly 75% presented with severe disease. Patients had altered biochemical profiles and treated with different drugs including antibiotics and steroids. Young age and malnutrition were two characteristic features. Only one third got intensive care support. The most common cause of death was acute respiratory syndrome (95.37%). Septic shock & acute myocardial infarction were predominantly early and uremia, hepatic failure & hyperglycemic crisis were the predominant causes of late hospital death.Conclusions The findings of this study will help clinicians as well as policy makers to take necessary steps to prevent death from COVID-19 in Bangladeshi population.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNo funding was associated with this workAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The institutional review board of the Biomedical Research Foundation, Bangladesh, approved the study protocol (Ref. no: BRF/ERB/2020/003).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll available data has been included